CoChat

The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research

von Arx, Lill-Brith, Kjær, Trine · 2014 · The Patient - Patient-Centered Outcomes Research
Cited by 42

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40271-014-0057-0

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 82

  1. Mitka M. Monitoring glycemic control in diabetes: new standardized reference measure a useful tool. JAMA. 2007;298(19):2252. · doi:10.1001/jama.298.19.2252
  2. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complicat. 2004;18(1):60–8. · DOI
  3. Jordan JL, Ellis SJ, Chambers R. Defining shared decision making and concordance: are they one and the same? Postgrad Med J. 2002;78(921):383–4. · DOI
  4. Snow R, Humphrey C, Sandall J. What happens when patients know more than their doctors? Experiences of health interactions after diabetes patient education: a qualitative patient-led study. BMJ Open. 2013;3(11):e003583. · DOI · Paper page
  5. Golin CE, DiMatteo MR, Gelberg L. The role of patient participation in the doctor visit. Implications for adherence to diabetes care. Diabetes Care. 1996;19(10):1153–64. · DOI · Paper page
  6. Gabbay M, Shiels C, Bower P, Sibbald B, King M, Ward E. Patient-practitioner agreement: does it matter? Psychol Med. 2003;33(2):241–51. · DOI · Paper page
  7. Cvengros JA, Christensen AJ, Hillis SL, Rosenthal GE. Patient and physician attitudes in the health care context: attitudinal symmetry predicts patient satisfaction and adherence. Ann Behav Med. 2007;33(3):262–8. · DOI
  8. Muhlbacher AC, Juhnke C. Patient preferences versus physicians’ judgement: does it make a difference in healthcare decision making? Appl Health Econ Health Policy. 2013;11(3):163–80. · DOI · Paper page
  9. Chin MH, Drum ML, Jin L, Shook ME, Huang ES, Meltzer DO. Variation in treatment preferences and care goals among older patients with diabetes and their physicians. Med Care. 2008;46(3):275–86. · DOI
  10. Porzsolt F, Clouth J, Deutschmann M, Hippler HJ. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes. 2010;8:125. · DOI
  11. Zulman DM, Kerr EA, Hofer TP, Heisler M, Zikmund-Fisher BJ. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. J Gen Intern Med. 2010;25(5):408–14. · DOI
  12. Casparie AF, van der Waal MA. Differences in preferences between diabetic patients and diabetologists regarding quality of care: a matter of continuity and efficiency of care? Diabet Med. 1995;12(9):828–32. · DOI
  13. van der Waal MA, Casparie AF, Lako CJ. Quality of care: a comparison of preferences between medical specialists and patients with chronic diseases. Soc Sci Med. 1996;42(5):643–9. · DOI
  14. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355(9220):2037–40. · DOI · Paper page
  15. Hanley B, Truesdale A, King A, Elbourne D, Chalmers I. Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. BMJ. 2001;322(7285):519–23. · DOI · Paper page
  16. Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013;369(5):397–400. · DOI
  17. Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the food and drug administration, February 16, 2001. Value Health. 2003;6(5):522–31. · DOI · Paper page
  18. Hareendran A, Gnanasakthy A, Winnette R, Revicki D. Capturing patients’ perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012;33(1):23–8. · DOI
  19. Bateman IJ, Carson RT, Day B, Hanemann M, Hanley N, Hett T, et al. Economic valuation with stated preference techniques: a manual. Cheltenham: Edward Elgar Publishing Ltd; 2002. · DOI · Paper page
  20. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320(7248):1530–3. · DOI · Paper page
  21. Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy. 2003;2(1):55–64.
  22. Louviere JJ, Woodworth G. Design and analysis of simulated consumer choice or allocation experiments: an approach based on aggregate data. J Market Res 1983;20:350–67. · DOI · Paper page
  23. Lin PJ, Cangelosi MJ, Lee DW, Neumann PJ. Willingness to pay for diagnostic technologies: a review of the contingent valuation literature. Value Health. 2013;16(5):797–805. · DOI
  24. Oremus M, Tarride JE. A systematic review of the use of contingent valuation in Alzheimer’s disease research. Dementia. 2008;7(4):461–80. · DOI
  25. Diener A, O’Brien B, Gafni A. Health care contingent valuation studies: a review and classification of the literature. Health Econ. 1998;7(4):313–26. · DOI · Paper page
  26. Ahola AJ, Groop PH. Barriers to self-management of diabetes. Diabet Med. 2013;30(4):413–20. · DOI · Paper page
  27. Patrick AR, Fischer MA, Choudhry NK, Shrank WH, Seeger JD, Liu J, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2014;29(2):320–7. · DOI
  28. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. · DOI · Paper page
  29. Guimaraes C, Marra CA, Gill S, Simpson S, Meneilly G, Queiroz RH, et al. A discrete choice experiment evaluation of patients’ preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management. Patient Prefer Adherence. 2010;4:433–40. · DOI
  30. Guimaraes C, Marra CA, Colley L, Gill S, Simpson S, Meneilly G, et al. Socioeconomic differences in preferences and willingness-to-pay for insulin delivery systems in type 1 and type 2 diabetes. Diabetes Technol Ther. 2009;11(9):567–73. · DOI
  31. Guimaraes C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, et al. A valuation of patients’ willingness-to-pay for insulin delivery in diabetes. Int J Technol Assess Health Care. 2009;25(3):359–66. · doi:10.1017/s0266462309990055
  32. van Gils PF, Lambooij MS, Flanderijn MH, van den Berg M, de Wit GA, Schuit AJ, et al. Willingness to participate in a lifestyle intervention program of patients with type 2 diabetes mellitus: a conjoint analysis. Patient Prefer Adherence. 2011;5:537–46. · DOI
  33. van Gils PF, Lambooij MS, Struijs JN, Flanderijn MH, van den Berg M, van den Berg B. Factors influencing valuation of- and willingness to participate in-A lifestyle intervention: an exploratory conjoint analysis with diabetes type 2 patients. Value Health. 2010;13(7):A296. · doi:10.1016/s1098-3015(11)72125-8
  34. Schiotz M, Bogelund M, Almdal T, Willaing I. Discrete choice as a method for exploring education preferences in a Danish population of patients with type 2 diabetes. Patient Educ Couns. 2012;87(2):217–25. · DOI
  35. Chang K. Comorbidities, quality of life and patients’ willingness to pay for a cure for type 2 diabetes in Taiwan. Public Health. 2010;124(5):284–94. · DOI
  36. Yen SH. Characterising patients’ preferences for information in doctor-patient interactions. Malays J Econ Stud. 2006;43(1–2):1–18.
  37. Jacobsson F, Johannesson M, Borgquist L. Is altruism paternalistic? Econ J. 2007;117(520):761–81. · DOI
  38. Chen TT, Chung KP, Huang HC, Man LN, Lai MS. Using discrete choice experiment to elicit doctors’ preferences for the report card design of diabetes care in Taiwan—a pilot study. J Eval Clin Pract. 2010;16(1):14–20. · DOI
  39. Taylor S, Hourihan F, Krass I, Armour C. Measuring consumer preference for models of diabetes care delivered by pharmacists. Pharm Pract. 2009;7(4):195–204.
  40. Basoglu N, Daim TU, Topacan U. Determining patient preferences for remote monitoring. J Med Syst. 2012;36(3):1389–401. · DOI
  41. Hoerger TJ, Johnson FR, Manjunath R, Mansfield C, Clayton LJ, Zhang P. High-risk individuals’ stated preferences and willingness-to-pay for diabetes risk-reduction programs. Diabetes. 2005;54(Suppl. 1):A611.
  42. Al-Haddad M, Ibrahim MMI, Sulaiman SAS, Shafie AA, Maarup N. Cost benefit analysis of the diabetes self management program at a university health centre in Malaysia. J Clin Diagn Res. 2010;4(3):2521–30.
  43. Bamer JC. Patient willingness to pay for diabetes disease state management programs. J Manag Pharm Care. 2001;1(2):85–95.
  44. Cairns JA, Van Der Pol MM. The estimation of marginal time preference in a UK-wide sample (TEMPUS) project. Health Technol Assess 2000;4(1):i-iv, 1–83. · DOI
  45. Sadri H. Contingent valuation of inhaled insulin: a canadian perspective. J Med Econ. 2007;10(4):475–87. · DOI
  46. Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B. Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care. 2005;28(9):2243–5. · DOI
  47. Aristides M, Weston AR, FitzGerald P, Reun CL, Maniadakis N. Patient preference and willingness-to-pay for Humalog Mix25 relative to humulin 30/70: a multicountry application of a discrete choice experiment. Value Health. 2004;7(4):442–54. · DOI
  48. Bøgelund M, Vilsboll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark—a discrete choice experiment. Curr Med Res Opin. 2011;27(11):2175–83. · DOI
  49. Jendle J, Torffvit O, Ridderstrale M, Lammert M, Ericsson A, Bogelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010;26(4):917–23. · DOI
  50. Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–24. · DOI · Paper page
  51. Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M. Economic-evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics. 1998;13(3):347–58. · DOI
  52. Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011;65(4):408–14. · DOI
  53. Gelhorn HL, Stringer SM, Brooks A, Thompson C, Monz BU, Boye KS, et al. Preferences for medication attributes among patients with type 2 diabetes mellitus in the United Kingdom. Diabetes Obes Metab. 2013;15(9):802–9. · DOI
  54. Pinto SL, Holiday-Goodman M, Black CD, Lesch D. Identifying factors that affect patients’ willingness to pay for inhaled insulin. Res Social Adm Pharm. 2009;5(3):253–61. · doi:10.1016/j.sapharm.2008.10.001
  55. Sadri H, MacKeigan LD, Leiter LA, Einarson TR. Willingness to pay for inhaled insulin: a contingent valuation approach. Pharmacoeconomics. 2005;23(12):1215–27. · DOI
  56. Lloyd A, Nafees B, Barnett AH, Heller S, Ploug UJ, Lammert M, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258–67. · DOI
  57. Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products—liraglutide and exenatide—for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61. · DOI · Paper page
  58. Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, et al. Conjoint analysis applications in health—how are studies being designed and reported?: an update on current practice in the published literature between 2005 and 2008. Patient. 2010;3(4):249–56. · DOI · Paper page
  59. Alsahli M, Gerich JE. Hypoglycemia. Endocrinol Metab Clin North Am. 2013;42(4):657–76. · DOI
  60. Walker EA, Usher JA. Understanding and enhancing adherence in adults with diabetes. Curr Diab Rep. 2003;3(2):141–8. · DOI
  61. Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32(9):507–10. · DOI · Paper page
  62. Tests of Glycemia in Diabetes. Diabetes Care. 2003;26(suppl 1):s106–8.
  63. Iqbal N, Morgan C, Maksoud H, Idris I. Improving patients’ knowledge on the relationship between HbA1c and mean plasma glucose improves glycaemic control among persons with poorly controlled diabetes. Ann Clin Biochem. 2008;45(5):504–7. · DOI
  64. Hanas R, John G, On behalf of the International. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care. 2010;33(8):1903–4. · DOI · Paper page
  65. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10(7):495–506. · DOI · Paper page
  66. Evans M, Khunti K, Mamdani M, Galbo-Jorgensen CB, Gundgaard J, Bogelund M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90. · DOI · Paper page
  67. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523–34. · DOI · Paper page
  68. Polonsky WH, Davis CL, Jacobson AM, Anderson BJ. Correlates of hypoglycemic fear in type I and type II diabetes mellitus. Health Psychol. 1992;11(3):199–202. · doi:10.1037/0278-6133.11.3.199 · Paper page
  69. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127–42. · DOI · Paper page
  70. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799–812. · DOI · Paper page
  71. Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34(3):511–7. · DOI · Paper page
  72. Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin. 2009;25(6):1413–20. · DOI · Paper page
  73. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28(11):2673–9. · DOI · Paper page
  74. Boxall PC, Adamowicz WL, Swait J, Williams M, Louviere J. A comparison of stated preference methods for environmental valuation. Ecol Econ. 1996;18(3):243–53. · DOI · Paper page
  75. Gagnon MP, Desmartis M, Lepage-Savary D, Gagnon J, St-Pierre M, Rhainds M, et al. Introducing patients’ and the public’s perspectives to health technology assessment: a systematic review of international experiences. Int J Technol Assess Health Care. 2011;27(1):31–42. · DOI · Paper page
  76. Hansen HP, Draborg E, Kristensen FB. Exploring qualitative research synthesis: the role of patients’ perspectives in health policy design and decision making. Patient. 2011;4(3):143–52. · DOI
  77. Facey K, Boivin A, Gracia J, Hansen HP, Lo SA, Mossman J, et al. Patients’ perspectives in health technology assessment: a route to robust evidence and fair deliberation. Int J Technol Assess Health Care. 2010;26(3):334–40. · DOI · Paper page
  78. Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care. 2007;23(1):30–5. · DOI · Paper page
  79. Knottnerus JA, Tugwell P. The patients’ perspective is key, also in research. J Clin Epidemiol. 2012;65(6):581–3. · DOI
  80. Bridges JF. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy. 2003;2(4):213–24.
  81. Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess. 2001;5(5):1–186. · DOI · Paper page
  82. Coast J, McDonald R, Baker R. Issues arising from the use of qualitative methods in health economics. J Health Serv Res Policy. 2004;9(3):171–6. · DOI

Cited by

See all 42

Metadata

Authors
von Arx, L.-B., & Kjær, T.
Venue
The Patient - Patient-Centered Outcomes Research
Published
2014-04-02
Volume
7
Issue
3
Pages
283-300
ISSN
  • 1178-1653
  • 1178-1661
Cited by
42
References
7
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research. https://app.cochat.ai/papers/10.1007/s40271-014-0057-0
The paper
von Arx, L.-B., & Kjær, T. (2014). The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research. The Patient - Patient-Centered Outcomes Research. https://doi.org/10.1007/s40271-014-0057-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.